<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31819203</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5462</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>3-4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Gene therapy</Title><ISOAbbreviation>Gene Ther</ISOAbbreviation></Journal><ArticleTitle>The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model.</ArticleTitle><Pagination><StartPage>157</StartPage><EndPage>169</EndPage><MedlinePgn>157-169</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41434-019-0116-1</ELocationID><Abstract><AbstractText>The superoxide dismutase 1 (SOD1) mutation is one of the most notable causes of amyotrophic lateral sclerosis (ALS), and modifying the mutant SOD1 gene is the best approach for the treatment of patients with ALS linked to the mutations in this gene. Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas9)/sgRNA delivered by the adeno-associated virus (AAV) system is a powerful tool for genome editing in the central nervous system (CNS). Here, we tested the capacity of the AAV-SaCas9-sgRNA system to modify mutant SOD1 in SOD1G93A transgenic mice and found that AAV9-SaCas9-sgRNA5 deleted the SOD1 gene, improved the lifespan of SOD1G93A mice by 54.6%, and notably ameliorated the performance of ALS transgenic mice. An immunochemical analysis showed that the expression of mutant SOD1 was very weak in motor neurons expressing SaCas9-sgRNA5. Consequently, the area showing muscle atrophy was more notably restored in the group treated with SaCas9-sgRNA5 compared with the group treated with SaCas9-sgLacZ. In addition, deep sequencing did not show the indel mutation in the gene highly matched to sgRNA5. Hence, AAV9-SaCas9-sgRNA-based gene editing is a feasible potential treatment for patients with ALS linked to SOD1 mutations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Weisong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurological Laboratory of Hebei Province, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiocerebrovascular Disease, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Moran</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurological Laboratory of Hebei Province, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Le</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurological Laboratory of Hebei Province, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yakun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurological Laboratory of Hebei Province, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhongyao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurological Laboratory of Hebei Province, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiocerebrovascular Disease, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yanqin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Jiangsu Nhwa Pharm. Co., Ltd, Nantong, Jiangsu, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guisen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Jiangsu Nhwa Pharm. Co., Ltd, Nantong, Jiangsu, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yaling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurological Laboratory of Hebei Province, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiocerebrovascular Disease, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurological Laboratory of Hebei Province, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiocerebrovascular Disease, Shijiazhuang, 050000, Hebei, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xueqin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, PR China. sxq5679@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurological Laboratory of Hebei Province, Shijiazhuang, 050000, Hebei, PR China. sxq5679@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiocerebrovascular Disease, Shijiazhuang, 050000, Hebei, PR China. sxq5679@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chunyan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, PR China. hebeichunyanli@aliyun.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurological Laboratory of Hebei Province, Shijiazhuang, 050000, Hebei, PR China. hebeichunyanli@aliyun.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiocerebrovascular Disease, Shijiazhuang, 050000, Hebei, PR China. hebeichunyanli@aliyun.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Gene Ther</MedlineTA><NlmUniqueID>9421525</NlmUniqueID><ISSNLinking>0969-7128</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017394">RNA, Guide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="Y">CRISPR-Cas Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="Y">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="N">Gene Editing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017394" MajorTopicYN="N">RNA, Guide, Kinetoplastida</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31819203</ArticleId><ArticleId IdType="doi">10.1038/s41434-019-0116-1</ArticleId><ArticleId IdType="pii">10.1038/s41434-019-0116-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 1993;92:689&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.3.689</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18:327&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80272-X</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Investig. 2018;128:3558&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1225829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1231143</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol. 2015;33:102&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3055</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520:186&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14299</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T, Ojala DS, Ekman FK, Byrne LC, Limsirichai P, Schaffer DV. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci Adv. 2017;3:eaar3952. https://doi.org/10.1126/sciadv.aar3952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aar3952.</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId><ArticleId IdType="pmc">5738228</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GM, Erwin KL, Byers N, Deitch JS, Augelli BJ, Blankenhorn EP, et al. Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res. 2004;130:7&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molbrainres.2004.07.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JY, Grunke SD, Levites Y, Golde TE, Jankowsky JL. Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. J Vis Exp. 2014;15:51863.</Citation></Reference><Reference><Citation>Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med. 2005;11:429&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1205</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med. 2005;11:423&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvanov AA, Mukhamedyarov MA, Palot&#xe1;s A, Islamov RR. Retrogradely transported siRNA silences human mutant SOD1 in spinal cord motor neurons. Exp Brain Res. 2009;195:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00221-009-1742-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70:201&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.593</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1515</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders NR, Joakim EkC, Dziegielewska KM. The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9. Nat Biotechnol. 2009;9:804&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt0909-804</ArticleId></ArticleIdList></Reference><Reference><Citation>Armbruster N, Lattanzi A, Jeavons M, Van Wittenberghe L, Gjata B, Marais T, et al. Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy. Mol Ther Methods Clin Dev. 2016;3:16060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtm.2016.60</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabebordbar M, Zhu K, Cheng JK, Chew WL, Widrick JJ, Yan WX, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016;351:407&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad5177</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351:403&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad5143</ArticleId></ArticleIdList></Reference><Reference><Citation>Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351:400&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad5725</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992;326:1464&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199205283262204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998;20:589&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80997-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA. 2002;99:1604&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.032539299</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong J, Huang C, Bi F, Wu Q, Huang B, Liu X, et al. Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. EMBO J. 2013;32:1917&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2013.122</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, et al. Microglia induce motor neuron death via the classical NF-&#x3ba;B pathway in amyotrophic lateral sclerosis. Neuron. 2014;8:1009&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine SM, Angel RA, Perry SW, Epstein LG, Rothstein JD, Dewhurst S, et al. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J Biol Chem. 1996;271:15303&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.26.15303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouali Alami N, Schurr C, Olde Heuvel F, Tang L, Li Q, Tasdogan A, et al. NF-&#x3ba;B activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. EMBO J. 2018;37:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798697</ArticleId></ArticleIdList></Reference><Reference><Citation>de Belleroche J, Orrell R, King A. Familial amyotrophic lateral sclerosis/motor neurone disease (FALS): a review of current developments. J Med Genet. 1995;32:841&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.32.11.841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers ML, Smith KS, Matusica D, Fenech M, Hoffman L, Rush RA, et al. Non-viral gene therapy that targets motor neurons in vivo. Front Mol Neurosci. 2014;7:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2014.00080</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>